Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies

International Journal of Antimicrobial Agents

Volumn 39, Issue 6, 2012, Pages 510-513

  Hoenigl, Martin ^a   Raggam, Reinhard B ^b   Salzer, Helmut J F ^a   Valentin, Thomas ^a   Valentin, Angelika ^a   Zollner Schwetz, Ines ^a   Strohmeier, Anna T ^a   Seeber, Katharina ^a   Wölfler, Albert ^a   Sill, Heinz ^a   Krause, Robert ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL GRAZ   (Austria)

Author keywords

Antifungal prophylaxis; Antifungal therapy; Haematological malignancy; Posaconazole plasma concentration; Therapeutic drug monitoring

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ECHINOCANDIN; POSACONAZOLE;

ADULT; CANCER PATIENT; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; INVASIVE MOULD INFECTION; LIVER TOXICITY; LOW DRUG DOSE; MALE; MYCOSIS; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; RISK FACTOR;

ADULT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CHEMOPREVENTION; DRUG MONITORING; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; RISK FACTORS; TRIAZOLES; YOUNG ADULT;

EID: 84860477358     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.02.002     Document Type: Conference Paper

References (28)

1. M. Hoenigl, T. Valentin, H.J. Salzer, I. Zollner-Schwetz, and R. Krause Underestimating the real burden of invasive fungal infections in hematopoietic stem cell transplant recipients? Clin Infect Dis 51 2010 253 254 [author reply 254-5]
2. D.P. Kontoyiannis, K.A. Marr, B.J. Park, B.D. Alexander, E.J. Anaissie, and T.J. Walsh Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database Clin Infect Dis 50 2010 1091 1100
3. W.J. Smith, R.H. Drew, and J.R. Perfect Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update Expert Rev Anti Infect Ther 7 2009 165 181
4. D.T. Wilson, R.H. Drew, and J.R. Perfect Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update Mycopathologia 168 2009 313 327
5. D. Al-Badriyeh, M. Slavin, D. Liew, K. Thursky, M. Downey, and A. Grigg Pharmacoeconomic evaluation of voriconazole versus posaconazole for antifungal prophylaxis in acute myeloid leukaemia J Antimicrob Chemother 65 2010 1052 1061
6. S. Perkhofer, C. Lass-Florl, M. Hell, G. Russ, R. Krause, and M. Honigl The nationwide Austrian Aspergillus registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients Int J Antimicrob Agents 36 2010 531 536
7. J.J. Vehreschild, M.J. Ruping, H. Wisplinghoff, F. Farowski, A. Steinbach, and R. Sims Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort J Antimicrob Chemother 65 2010 1466 1471
8. T.J. Walsh, I. Raad, T.F. Patterson, P. Chandrasekar, G.R. Donowitz, and R. Graybill Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2007 2 12 (Pubitemid 44968977)
9. S.J. Howard, J.M. Lestner, A. Sharp, L. Gregson, J. Goodwin, and J. Slater Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy J Infect Dis 203 2011 1324 1332
10. O.A. Cornely, J. Maertens, D.J. Winston, J. Perfect, A.J. Ullmann, and T.J. Walsh Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359 (Pubitemid 46148777)
11. A.J. Ullmann, J.H. Lipton, D.H. Vesole, P. Chandrasekar, A. Langston, and S.R. Tarantolo Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 2007 335 347 (Pubitemid 46148776)
12. I.I. Raad, J.R. Graybill, A.B. Bustamante, O.A. Cornely, V. Gaona-Flores, and C. Afif Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections Clin Infect Dis 42 2006 1726 1734 (Pubitemid 43839438)
13. D. Andes, A. Pascual, and O. Marchetti Antifungal therapeutic drug monitoring: established and emerging indications Antimicrob Agents Chemother 53 2009 24 34
14. C. Ustun, D.L. DeRemer, J.C. Steele Jr., C. Forseen, J.F. Fisher, and A.P. Jillella Fatal Aspergillus fumigatus and Candida glabrata infections with posaconazole prophylaxis after stem cell transplantation Int J Antimicrob Agents 32 2008 365 366
15. A.M. Bryant, D. Slain, A. Cumpston, and M. Craig A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis Int J Antimicrob Agents 37 2011 266 269
16. D. Lebeaux, F. Lanternier, C. Elie, F. Suarez, A. Buzyn, and J.P. Viard Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults Antimicrob Agents Chemother 53 2009 5224 5229
17. G. Krishna, A. Moton, L. Ma, M.M. Medlock, and J. McLeod Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 2009 958 966
18. R.K. Shields, C.J. Clancy, A. Vadnerkar, E.J. Kwak, F.P. Silveira, and R.C. Massih Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy Antimicrob Agents Chemother 55 2011 1308 1311
19. M. Michallet, M. Sobh, S. Morisset, S. Kraghel, F.E. Nicolini, and X. Thomas Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole Med Mycol 49 2011 681 687
20. J. Smith, and D. Andes Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations Ther Drug Monit 30 2008 167 172 (Pubitemid 351521643)
21. M.J. Ruping, N. Albermann, F. Ebinger, I. Burckhardt, C. Beisel, and C. Muller Posaconazole concentrations in the central nervous system J Antimicrob Chemother 62 2008 1468 1470
22. A. Calcagno, L. Baietto, F.G. De Rosa, M.C. Tettoni, V. Libanore, and R. Bertucci Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis J Antimicrob Chemother 66 2011 224 225
23. M. Hoenigl, I. Zollner-Schwetz, H. Sill, W. Linkesch, C. Lass-Flörl, and W.J. Schnedl Epidemiology of invasive fungal infections and rationale for antifungal therapy in patients with haematological malignancies Mycoses 54 2011 454 459
24. B. De Pauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, and T. Calandra Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 2008 1813 1821
25. M. Hoenigl, H.J. Salzer, R.B. Raggam, T. Valentin, A. Rohn, and A. Wölfler Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies Med Mycol 2012 10.3109/13693786.2011.603102
26. R. de la Camara, I. Jarque, M.A. Sanz, S. Grau, M.A. Casado, and F.J. Sabater Economic evaluation of posaconazole vs fluconazole in the prevention of invasive fungal infections in patients with GVHD following haematopoietic SCT Bone Marrow Transplant 45 2010 925 932
27. J. Hahn, F. Stifel, A. Reichle, E. Holler, and R. Andreesen Clinical experience with posaconazole prophylaxis - a retrospective analysis in a haematological unit Mycoses 54 Suppl. 1 2011 12 16
28. I. Sánchez-Ortega, B. Patiño, M. Arnan, T. Peralta, R. Parody, and C. Gudiol Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation Bone Marrow Transplant 46 2011 733 739